Effector-Null Antibody Expression Vectors

Silenced Fc variants engineered with LALA, LALA-PG, EN, N297Q, and related mutations to reduce Fc-mediated effector functions.

Effector-Null Antibody Expression Vector Selection Guide

Compare seven Fc-engineered antibody expression vectors to select an appropriate effector-attenuated variant for your research.

Catalog No. Variant Engineering Mechanism Selection Guidance
AFV-04 Human IgG1 (EN) Lower-hinge and CH2 engineering Broad Fc-effector attenuation studies
AFV-13 Human IgG1 (LALA-PG) L234A / L235A / P329G Strong Fc-effector attenuation
AFV-12 Human IgG1 (LALA) L234A / L235A Established Fc-silencing benchmark
AFV-05 Human IgG1 (N297Q) N297Q; removal of Fc N-glycosylation site Aglycosylated Fc comparison
AFV-16 Human IgG1 (ΔG236) Deletion of G236 Alternative FcγR-interaction engineering
AFV-14 Mouse IgG2a (LALA-PG) L234A / L235A / P329G Mouse IgG2a effector attenuation
AFV-15 Mouse IgG2a (N297Q) N297Q; removal of Fc N-glycosylation site Mouse IgG2a aglycosylation studies

Functional attenuation depends on antibody sequence, Fc receptor, assay system, and experimental conditions. Confirm FcγR binding, C1q binding, and effector activity as appropriate.

Showing all 7 results